| Wang, Shu |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05576389: Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer |
|
|
| Enrolling by invitation | 2 | 94 | RoW | Camrelizumab+Fluzoparib | Peking University People's Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Germline BRCA-mutated HER2-negative Breast Cancer | 04/24 | 12/26 | | |
NCT06592625: Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients |
|
|
| Not yet recruiting | 2 | 60 | RoW | SHR-A1811, Adebrelimab | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Untreated Early-stage or Locally Advanced Breast Cancer | 02/26 | 02/26 | | |
NCT04750122: Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients |
|
|
| Recruiting | 1/2 | 46 | RoW | neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning, docetaxel and trastuzumab and pertuzumab, docetaxel and carboplatin and trastuzumab and pertuzumab | Peking University People's Hospital | HER2-positive Early Breast Cancer | 06/22 | 12/26 | | |
NCT04836156: Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients |
|
|
| Recruiting | 1/2 | 46 | RoW | neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, docetaxel and carboplatin, docetaxel and epirubicin, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer, docetaxel and cyclophosphamide, epirubicin and cyclophosphamide | Peking University People's Hospital | HER2-negative Early Breast Cancer | 06/22 | 12/26 | | |
NacHER2, NCT06700369: De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients |
|
|
| Recruiting | N/A | 519 | RoW | | Shu Wang | HER2-positive Breast Cancer | 12/28 | 12/31 | | |
NCT02691624: Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation |
|
|
| Active, not recruiting | N/A | 100 | RoW | | Peking University People's Hospital | Lymphedema of Upper Arm | 05/16 | 12/21 | | |
| Recruiting | N/A | 380 | RoW | | Peking University People's Hospital | Triple Negative Breast Cancer | 12/28 | 12/28 | | |
NeoTNBCX, NCT06700382: Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC |
|
|
| Recruiting | N/A | 1166 | RoW | capecitabine | Shu Wang | Triple Negative Breast Cancer | 12/31 | 12/31 | | |
nonPHER, NCT06693037: Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy |
|
|
| Recruiting | N/A | 2092 | RoW | | Shu Wang | HER2-positive Breast Cancer | 12/31 | 12/31 | | |
| Recruiting | N/A | 2806 | RoW | neratinib | Shu Wang | HER2-positive Breast Cancer | 12/31 | 12/31 | | |
NCT03640117: The Value of Geriatric Assessments in Older Patients With Breast Cancer |
|
|
| Recruiting | N/A | 200 | RoW | | Peking University People's Hospital | Aging, Breast Cancer, Chemotherapeutic Toxicity, Survival | 05/22 | 05/25 | | |
NCT03791853: Light-CT in the Diagnosis of Breast Tumor and Lymph Node |
|
|
| Recruiting | N/A | 150 | RoW | Light-CT | Peking University People's Hospital | Breast Neoplasms | 12/22 | 12/23 | | |
PROOF, NCT02430103: Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients |
|
|
| Active, not recruiting | N/A | 349 | RoW | Goserelin 3.6 MG, Zoladex | Peking University People's Hospital | Breast Cancer | 12/23 | 12/24 | | |
NCT03105570: The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study |
|
|
| Recruiting | N/A | 145 | RoW | Areola Sparing Mastectomy, Nipple coring | Peking University People's Hospital | Breast Neoplasms | 05/24 | 05/24 | | |
| Recruiting | N/A | 190 | RoW | Imatinib, treat | Xijing Hospital | GIST | 09/24 | 09/25 | | |
NCT04996615: Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women |
|
|
| Recruiting | N/A | 5000 | RoW | no intervention | Peking University People's Hospital | Breast Cancer, Magnetic Resonance Imaging | 09/25 | 09/25 | | |
NCT04824378: Study on Classification Method of Indocyanine Green Lymphography Based on Deep Learning |
|
|
| Recruiting | N/A | 200 | RoW | No Intervention. | Peking University People's Hospital | Breast Cancer Related Lymphedema, Deep Learning | 10/22 | 10/22 | | |
NCT05634798: An Observational Study Based on Endometrial Cancer Risk Screening Model |
|
|
| Recruiting | N/A | 2000 | RoW | no intervention | Peking Union Medical College Hospital | Endometrial Neoplasms | 12/23 | 12/23 | | |
